Join
Eiger BioPharmaceuticals Inc. logo

EIGR

NASDAQ

Eiger BioPharmaceuticals Inc.

SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)IPO2014
$1.73-0.15 (-8.24%)
News25/Ratings1

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. The company was founded in 2008 and is headquartered in Palo Alto, California.

Latest news

25 items

EIGR FAQ

7 questions
  • What does Eiger BioPharmaceuticals Inc. do?
    Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies...
  • Where does EIGR stock trade?
    Eiger BioPharmaceuticals Inc. (EIGR) is listed on NASDAQ.
  • What sector and industry is EIGR in?
    Eiger BioPharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.
  • When did Eiger BioPharmaceuticals Inc. go public?
    Eiger BioPharmaceuticals Inc. (EIGR) completed its IPO in 2014.
  • What are analysts saying about EIGR?
    Eiger BioPharmaceuticals Inc. has had 1 recent analyst action on file. The most recent action was from Citigroup: Buy with a $2700.00 price target on 2021-08-09. Recent price targets cluster around $2700.00.
  • What companies are similar to EIGR?
    Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare EIGR side-by-side with any of them on Quantisnow.
  • How can I track EIGR on Quantisnow?
    Quantisnow aggregates Eiger BioPharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow EIGR to receive live email and push alerts on every new disclosure.